OMQS · OMNIQ Corp.

The agreement and purchase price were paid on December 8, 2025, but the shares were not issued until February 17, 2026.

Options were granted pursuant to the Company's Equity Incentive Plan.

Options were granted pursuant to the Company's Equity Incentive Plan.

Options were granted pursuant to the Company's Equity Incentive Plan.

The shares were sold to cover an Israeli tax liability triggered by Mr. Nissenson's earlier cashless option exercises.

The shares were sold to cover an Israeli tax liability triggered by Mr. Nissenson's earlier cashless option exercises.

The shares were sold to cover an Israeli tax liability triggered by Mr. Nissenson's earlier cashless option exercises.

The shares were sold to cover an Israeli tax liability triggered by Mr. Nissenson's earlier cashless option exercises.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on March 6, 2023. In connection with the Company's 2018 Option Plan, 20,000 stock options were granted to Mr. MacMillan. On March 6, 2023, Mr. MacMillan exercised 20,000 options on a cashless basis. For this transaction, the number of shares received by Mr. MacMillan is 10,439. Following the net exercise, Mr. MacMillan has no remaining options from the grant on March 6, 2018.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on March 6, 2023. In connection with the Company's 2018 Option Plan, 20,000 stock options were granted to Mr. Shalem. On March 6, 2023, Mr. Shalem exercised 20,000 options on a cashless basis. For this transaction, the number of shares received by Mr. Shalem is 10,439. Following the net exercise, Mr. Shalem has no remaining options from the grant on March 6, 2018.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on March 6, 2023. In connection with the Company's 2018 Option Plan, 40,000 stock options were granted to Mr. Nissenson. On March 6, 2023, Mr. Nissenson exercised 20,000 options on a cashless basis. For this transaction, the number of shares received by Mr. Nissenson is 10,439. Following the net exercise, Mr. Nissenson has no remaining options from the grant on March 6, 2018.

The options were issued pursuant to a grant under the 2018 Equity Incentive Plan.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on March 6, 2023. In connection with the Company's 2018 Option Plan, On March 6, 2023, Mr. Lustgarten exercised 100,000 options on a cashless basis. For this transaction, the number of shares received by Mr. Lustgarten was 52,191. Following the net exercise, Mr. Lustgarten will have 0 remaining options from the grant on March 6, 2018.

The options were issued pursuant to a grant under the 2018 Equity Incentive Plan.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on March 6, 2023. In connection with the Company's 2018 Option Plan, 20,000 stock options were granted to Mr. MacMillan. On March 6, 2023, Mr. MacMillan exercised 20,000 options on a cashless basis. For this transaction, the number of shares received by Mr. MacMillan is 10,439. Following the net exercise, Mr. MacMillan has no remaining options from the grant on March 6, 2018.

The options were issued pursuant to a grant under the 2018 Equity Incentive Plan.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on March 6, 2023. In connection with the Company's 2018 Option Plan, 20,000 stock options were granted to Mr. Shalem. On March 6, 2023, Mr. Shalem exercised 20,000 options on a cashless basis. For this transaction, the number of shares received by Mr. Shalem is 10,439. Following the net exercise, Mr. Shalem has no remaining options from the grant on March 6, 2018.

The options were issued pursuant to a grant under the 2018 Equity Incentive Plan.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on March 6, 2023. In connection with the Company's 2018 Option Plan, On March 6, 2023, Mr. Lustgarten exercised 100,000 options on a cashless basis. For this transaction, the number of shares received by Mr. Lustgarten was 52,191. Following the net exercise, Mr. Lustgarten will have 0 remaining options from the grant on March 6, 2018.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on March 6, 2023. In connection with the Company's 2018 Option Plan, 40,000 stock options were granted to Mr. Nissenson. On March 6, 2023, Mr. Nissenson exercised 20,000 options on a cashless basis. For this transaction, the number of shares received by Mr. Nissenson is 10,439. Following the net exercise, Mr. Nissenson has no remaining options from the grant on March 6, 2018.

The Shares were granted to the Reporting Person in connection with his Employment Agreement and pursuant to the Issuer's 2021 Equity Incentive Plan.

Granted to replace the Restricted Stock granted to the Reporting Person on the Form 4 filed with the Commission on March 1, 2022 which restricted stock was cancelled.

Walefar Investments Ltd. holds 746,808 shares of the issuer's common stock, which is beneficially owned by the Reporting Person.

The Shares were granted to the Reporting Person in connection with a consulting agreement and pursuant to the Issuer's 2021 Equity Incentive Plan.

The Securities were granted to Campbeltown Consulting Ltd., which is beneficially owned by the Reporting Person.

Represents the closing price of the Issuer's common stock on August 30, 2022.

The Warrants vest equally in quarterly installments over a 2 year period.

The Securities were granted to Campbeltown Consulting Ltd., which is beneficially owned by the Reporting Person.

Granted to replace the Restricted Stock granted to the Reporting Person on the Form 4 filed with the Commission on March 1, 2022. which restricted stock was cancelled.

The stock options herein reflect grants to the Reporting Person pursuant to the OMNIQ Corp. 2021 Equity Incentive Plan. The stock options vest in even quarterly installments over 2 years and expire on March 1, 2027. Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

Each restricted share represents a contingent right to receive one share of the Issuer's common stock. 50% of the restricted shares vested on March 1, 2022, and 50% vest on March 1, 2023.

Each restricted share represents a contingent right to receive one share of the Issuer's common stock. 50% of the restricted shares vested on March 1, 2022, and 50% vest on March 1, 2023.

The stock options herein reflect grants to the Reporting Person pursuant to the OMNIQ Corp. 2021 Equity Incentive Plan. The stock options vest in even quarterly installments over 2 years and expire on March 1, 2027. Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

The stock options herein reflect grants to the Reporting Person pursuant to the OMNIQ Corp. 2021 Equity Incentive Plan. The stock options vest in even quarterly installments over 2 years and expire on March 1, 2027. Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

Each restricted share represents a contingent right to receive one share of the Issuer's common stock. 50% of the restricted shares vested on March 1, 2022, and 50% vest on March 1, 2023.

Each restricted share represents a contingent right to receive one share of the Issuer's common stock. 50% of the restricted shares vested on March 1, 2022, and 50% vest on March 1, 2023.

Walefar Investments Ltd. holds 746,808 shares of the issuer's common stock, which is beneficially owned by Mr. Lustgarten.

The stock options herein reflect grants to the Reporting Person pursuant to the OMNIQ Corp. 2021 Equity Incentive Plan. The stock options vest in even quarterly installments over 2 years and expire on March 1, 2027. Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

The stock options herein reflect grants to the Reporting Person pursuant to the OMNIQ Corp. 2021 Equity Incentive Plan. The stock options vest in even quarterly installments over 2 years and expire on March 1, 2027. Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

The stock options herein reflect grants to the Reporting Person pursuant to the OMNIQ Corp. 2021 Equity Incentive Plan. The stock options vest in even quarterly installments over 2 years and expire on March 1, 2027. Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

The stock options exercised herein reflect the cashless exercise of certain options issued on February 17, 2017 scheduled to expire on February 17, 2022. Following the Company's 1-for-20 reverse stock split of its common stock, effective November 20, 2019, the number of options to be exercised is 38,017.

Prior to the transaction reported herein, Walefar Investments Ltd. held 746,808 shares of the issuer's common stock, which is beneficially owned by Mr. Lustgarten.

The stock options exercised herein reflect the cashless exercise of certain options issued on February 17, 2017 scheduled to expire on February 17, 2022. Following the Company's 1-for-20 reverse stock split of its common stock, effective November 20, 2019, the number of options to be exercised is 38,017.

Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

The stock options exercised herein reflect the cashless exercise of certain options issued on February 17, 2017 scheduled to expire on February 17, 2022. Following the Company's 1-for-20 reverse stock split of its common stock, effective November 20, 2019, the number of options to be exercised is 76,033.

Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

The stock options exercised herein reflect the cashless exercise of certain options issued on February 17, 2017 scheduled to expire on February 17, 2022. Following the Company's 1-for-20 reverse stock split of its common stock, effective November 20, 2019, the number of options to be exercised is 76,033.

Prior to the transaction reported herein, Walefar Investments Ltd. held 746,808 shares of the issuer's common stock, which is beneficially owned by Mr. Lustgarten.

The shares were sold to cover an Israeli tax liability triggered by Mr. Nissenson's earlier cashless exercise of 25,000 post-split options that were scheduled to expire on August 2, 2021. As the Common Stock came into Mr. Nissenson's possession upon the vesting of shares issued under an equity incentive plan of the Company and are being used to satisfy the tax liability the sale was exempt from the Lock-Up Agreement entered into as part of the July Offering.

The shares were sold to cover an Israeli tax liability triggered by Mr. Nissenson's earlier cashless exercise of 25,000 post-split options that were scheduled to expire on August 2, 2021. As the Common Stock came into Mr. Nissenson's possession upon the vesting of shares issued under an equity incentive plan of the Company and are being used to satisfy the tax liability the sale was exempt from the Lock-Up Agreement entered into as part of the July Offering.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 500,000 stock options were granted to Mr. MacMillan on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options in the stock option grant is 25,000. For this transaction, the number of options to be exercised by Mr. MacMillan is 25,000. Following the net exercise, Mr. MacMillan will have 0 remaining options from this class of options within the August 2, 2017 stock option grant.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 500,000 stock options were granted to Mr. MacMillan on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options in the stock option grant is 25,000. For this transaction, the number of options to be exercised by Mr. MacMillan is 25,000. Following the net exercise, Mr. MacMillan will have 0 remaining options from this class of options within the August 2, 2017 stock option grant.

Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 500,000 stock options were granted to Mr. Shalem on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options in the stock option grant is 25,000. For this transaction, the number of options to be exercised by Mr. Shalem is 25,000. Following the net exercise, Mr. Shalem will have 0 remaining options from this class of options within the August 2, 2017 stock option grant.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 500,000 stock options were granted to Mr. Shalem on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options in the stock option grant is 25,000. For this transaction, the number of options to be exercised by Mr. Shalem is 25,000. Following the net exercise, Mr. Shalem will have 0 remaining options from this class of options within the August 2, 2017 stock option grant.

Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 500,000 stock options were granted to Mr. Nissenson on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options is 25,000. On April 8, 2021, Mr. Nissenson exercised 2,500 options on a cashless basis. For this transaction, the number of options to be exercised by Mr. Nissenson is 22,500. Following the net exercise, Mr. Nissenson will have 0 remaining options from the grant on August 2, 2017.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 500,000 stock options were granted to Mr. Nissenson on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options is 25,000. On April 8, 2021, Mr. Nissenson exercised 2,500 options on a cashless basis. For this transaction, the number of options to be exercised by Mr. Nissenson is 22,500. Following the net exercise, Mr. Nissenson will have 0 remaining options from the grant on August 2, 2017.

Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis, after giving effect to the 20:1 reverse stock split.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 500,000 stock options were granted to Mr. Nissenson on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options is 25,000. The number of options to be exercised by Mr. Nissenson is 2,500. Following the net exercise, Mr. Nissenson will have 22,500 remaining options from the grant on August 2, 2017.

Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis, after giving effect to the 20:1 reverse stock split.

The warrants exercised herein reflect the cashless exercise of certain warrants scheduled to expire on August 2, 2021. In connection with a Consulting Agreement, 1,500,000 warrants were granted to Mr. Nissensohn on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of warrants to be exercised is 75,000. Following the net exercise, Mr. Nissensohn has no more options from the August 2017 grant.

Prior to the transaction reported herein, 729,308 shares of the issuer's common shares were held by Campbeltown Consulting Ltd., which is beneficially owned by Mr. Nissensohn.

The stock options exercised herein reflect the cashless exercise of certain options issued in August 2017 scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 1,500,000 stock options were granted to Mr. Lustgarten on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options to be exercised is 75,000. Following the net exercise, Mr. Lustgarten has no more options from the August 2017 grant.

Prior to the transaction reported herein, Walefar Investments Ltd. held 746,808 shares of the issuer's common stock, which is beneficially owned by Mr. Lustgarten.

The stock options exercised herein reflect the cashless exercise of certain options scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 500,000 stock options were granted to Mr. Nissenson on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options is 25,000. The number of options to be exercised by Mr. Nissenson is 2,500. Following the net exercise, Mr. Nissenson will have 22,500 remaining options from the grant on August 2, 2017.

Prior to the transaction reported herein, Mr. Nissenson directly held 10,000 shares of the issuer's common stock.

The stock options exercised herein reflect the cashless exercise of certain options issued in August 2017 scheduled to expire on August 2, 2021. In connection with the Company's 2014 Option Plan, 1,500,000 stock options were granted to Mr. Lustgarten on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of options to be exercised is 75,000. Following the net exercise, Mr. Lustgarten has no more options from the August 2017 grant.

Upon exercise, the underlying net options convert into shares of the issuer's common stock on a one-for-one basis, after giving effect to the 20:1 reverse stock split.

The warrants exercised herein reflect the cashless exercise of certain warrants scheduled to expire on August 2, 2021. In connection with a Consulting Agreement, 1,500,000 warrants were granted to Mr. Nissensohn on August 2, 2017. Following the Company's 1-for-20 reverse stock split of its common stock, effective, November 20, 2019, the number of warrants to be exercised is 75,000. Following the net exercise, Mr. Nissensohn has no more options from the August 2017 grant.

Upon exercise, the underlying net warrants convert into shares of the issuer's common stock on a one-for-one basis, after giving effect to the 20:1 reverse stock split.